Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous menstrual blood stem cells
- Development stage
- Unknown
- Lead developer
- Guiping People's Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrauterine, Hysteroscopic Injection, Intraovarian Injection, Local Injection, Topical
01
Overview
Autologous menstrual blood stem cells (MenSCs) are a type of mesenchymal stem cell (MSC) harvested from a patient's own menstrual blood. These cells are characterized by their high proliferative capacity, low immunogenicity, and multi-lineage differentiation potential, including the ability to differentiate into endometrial-like cells. In clinical applications, particularly for the treatment of infertility caused by moderate to severe intrauterine adhesions (Asherman's syndrome), MenSCs are typically delivered via intrauterine perfusion. They function primarily through paracrine mechanisms, secreting various growth factors and cytokines such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) that promote angiogenesis, reduce fibrotic scarring, and modulate the local immune environment to support endometrial regeneration and tissue repair.
- Other names
- autologous menstrual blood stem cellsautologous menstrual blood-derived mesenchymal stem cellsMenSCsMenSC
Beyond the preview
Go deeper on autologous menstrual blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous menstrual blood stem cells.